Capitalization 1.39B P/E ratio 2024 *
-5.9x
P/E ratio 2025 * -7.47x
Enterprise value 1.04B EV / Sales 2024 *
77.9x
EV / Sales 2025 * 14.3x
Free-Float
80.35%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart

Last Transcript: Day One Biopharmaceuticals, Inc.

1 day-3.33%
1 week-3.87%
Current month+11.68%
1 month+12.50%
3 months-7.51%
6 months+11.93%
Current year+5.41%
More quotes
1 week
14.62
Extreme 14.62
16.04
1 month
13.00
Extreme 13
16.27
Current year
11.94
Extreme 11.94
18.07
1 year
9.67
Extreme 9.67
18.07
3 years
5.44
Extreme 5.44
28.70
5 years
5.44
Extreme 5.44
28.70
10 years
5.44
Extreme 5.44
28.70
More quotes
Insider TitleAgeSince
Founder 55 18-10-31
Chief Executive Officer 52 20-08-31
Director of Finance/CFO 47 21-01-31
Insider TitleAgeSince
Chief Executive Officer 52 20-08-31
Director/Board Member 37 19-11-30
Director/Board Member 51 21-01-31
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-3.33%-3.87%+27.19%-31.99% 1.39B
-2.52%-5.55%-6.52%-66.12% 46.47B
-0.02%+2.48%+4.60%-4.15% 43.53B
+0.23%+1.63%+6.46%-25.94% 42.23B
+0.93%-5.34%+18.20%+29.64% 29.64B
+2.22%+2.49%+28.08%-23.59% 28.11B
-0.14%-4.17%+34.90%+52.19% 27.47B
-1.53%+1.04%+33.58%+79.66% 14.94B
+1.44%-2.77%-13.21%-34.56% 12.06B
+0.97%-2.16%+7.77%-43.88% 11.35B
Average +0.05%-1.17%+14.10%-6.87% 25.72B
Weighted average by Cap. +0.33%-0.92%+11.38%-9.60%
See all sector performances
Ratios2024 *2025 *
Net sales 14.91M 82.05M
Net income -237M -202M
Net Debt -229M -217M
More financial data * Estimated data
Logo Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its product candidates include tovorafenib, pimasertib and the VRK1 program. The Company’s lead product candidate, tovorafenib, is an investigational, oral, brain-penetrant, highly selective type II RAF kinase inhibitor. The Company’s pipeline also includes pimasertib, an investigational, oral, highly selective small molecule inhibitor of mitogen-activated protein kinases 1 and 2 (MEK-1/-2). It has initiated an open-label, multicenter, phase Ib/IIa umbrella master trial, or FIRELIGHT-1, of tovorafenib as a monotherapy or in combination, which consists of two substudies. Substudy 1 is a phase IIa trial of tovorafenib as a monotherapy in patients 12 years and older.
Employees
174
Related indices
More about the company
Date Price Change Volume
24-07-24 15.39 $ -3.33% 1,091,065
24-07-23 15.92 $ +7.06% 754,367
24-07-22 14.87 $ -0.73% 604,047
24-07-19 14.98 $ 0.00% 630,093
24-07-18 14.98 $ -4.28% 768,022

Delayed Quote Nasdaq, July 24, 2024 at 04:00 pm EDT

More quotes
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
15.39USD
Average target price
36.00USD
Spread / Average Target
+133.92%
Consensus